ArticleOpen veterinary journal2025
Computational insights in CD58 binding to ASFV CD2v and in silico optimization of nanobody designs against the interface.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of broadly neutralizing VmAbs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: African swine fever (ASF) continues to hamper pork production worldwide. In addition to vaccines, there is a need to develop curative therapeutics, such as highly-specific antibodies or nanobodies (NB), against immunogenic proteins with important functions such as the viral CD2 (CD2v)-like protein. However, further characterization of CD2v, such as its binding with cellular partners, is needed for the rational development of such biologics. Aim: We aimed to analyze the binding interaction of CD2v from pandemic genotypes I and II and swine CD58 using molecular simulations and optimize the NB to target the conserved epitope around the identified binding site using a computational pipeline. Methods: CD2v-CD58 complexes and equivalents from swine and humans were generated and simulated to characterize their binding. Mapping of residue contributions to the binding, variability, epitope propensity, and epitope multiplicity allowed us to select a conserved region near the site. Optimized NB were developed from sequences deposited in the NanoLAS repository, following screening for physicochemical and reactogenic parameters, docking, iterative optimization, and molecular dynamics simulations compared to controls. Results: Simulations report poor affinity of CD2v to CD58 in the "canonical" pose and present a novel pose backed by docking, simulation data, and recent observations. The new site might have developed due to immunological considerations and may reproduce observed lymphocyte non-proliferation by hijacking CD58-CD2 ruler functions in immunological synapse formation. Two NB were also developed targeting genotype I and II CD2vs with stable binding and better affinity, solubility, allergenicity, and antigenicity than the controls NB22 and 18a3. Conclusion: Herein, we showcase the power of computational biology techniques to elucidate ASF virus (ASFV)-host interactions and simultaneously design therapeutics to target the identified novel binding site. Further validation is needed to confirm these findings; however, future work on other relevant ASFV proteins may lead to potent cocktails with therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.